Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 2
2007 1
2012 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL, Disis ML. Knutson KL, et al. Cancer Immunol Immunother. 2005 Aug;54(8):721-8. doi: 10.1007/s00262-004-0653-2. Epub 2005 Jan 27. Cancer Immunol Immunother. 2005. PMID: 16010587 Review.
Adoptive T-cell therapy for the treatment of solid tumours.
Knutson KL, Almand B, Mankoff DA, Schiffman K, Disis ML. Knutson KL, et al. Expert Opin Biol Ther. 2002 Jan;2(1):55-66. doi: 10.1517/14712598.2.1.55. Expert Opin Biol Ther. 2002. PMID: 11772340 Review.
Clinical studies of vaccines targeting breast cancer.
Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG. Ko BK, et al. Clin Cancer Res. 2003 Aug 15;9(9):3222-34. Clin Cancer Res. 2003. PMID: 12960107 Free article. Review.
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.
Salazar LG, Coveler AL, Swensen RE, Gooley TA, Goodell V, Schiffman K, Disis ML. Salazar LG, et al. Clin Immunol. 2007 Dec;125(3):275-80. doi: 10.1016/j.clim.2007.08.006. Epub 2007 Oct 29. Clin Immunol. 2007. PMID: 17913588 Clinical Trial.
Augmenting T helper cell immunity in cancer.
Knutson KL, Disis ML. Knutson KL, et al. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):365-71. doi: 10.2174/156800805774913006. Curr Drug Targets Immune Endocr Metabol Disord. 2005. PMID: 16375690 Review.
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice.
Knutson KL, Almand B, Dang Y, Disis ML. Knutson KL, et al. Cancer Res. 2004 Feb 1;64(3):1146-51. doi: 10.1158/0008-5472.can-03-0173. Cancer Res. 2004. PMID: 14871850 Free article.
Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
Dang Y, Wagner WM, Gad E, Rastetter L, Berger CM, Holt GE, Disis ML. Dang Y, et al. Clin Cancer Res. 2012 Jun 1;18(11):3122-31. doi: 10.1158/1078-0432.CCR-12-0113. Epub 2012 Apr 17. Clin Cancer Res. 2012. PMID: 22510348 Free PMC article.
IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion.
Knutson KL, Disis ML. Knutson KL, et al. Clin Exp Immunol. 2004 Feb;135(2):322-9. doi: 10.1111/j.1365-2249.2004.02360.x. Clin Exp Immunol. 2004. PMID: 14738463 Free PMC article.
Immune system versus tumor: shifting the balance in favor of DCs and effective immunity.
Kaufman HL, Disis ML. Kaufman HL, et al. J Clin Invest. 2004 Mar;113(5):664-7. doi: 10.1172/JCI21148. J Clin Invest. 2004. PMID: 14991063 Free PMC article.